Company Overview

Monogram Orthopaedics is working to develop a product solution architecture with the long-term goal of enabling patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The Company has a robot prototype that can autonomously execute optimized paths for high precision insertion of implants in synthetic bone specimens. Monogram intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. The Company has not yet made 510(k) premarket notification submissions or obtained 510(k) clearances for any of its robotic products. FDA approval is required to market these products, and the Company has not obtained FDA approval for any of its robotic products, and it cannot estimate the timing, or assure the ability, to obtain such clearances.

Company Update Presentation

Monogram Orthopaedics First Quarter 2024 Update Call

PDF

Past Presentations

Monogram Management Presentation and Q&A (2023 FYE & Q4)
Thursday, March 21, 2024
VIEW

Analyst Coverage

Firm
Analyst
Zacks Small-Cap Research
Tom Kerr, CFA
Monogram Orthopaedics Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Monogram Orthopaedics Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Monogram Orthopaedics Inc. or its management. Monogram Orthopaedics Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations

Recent News

Transfer Agent

Equity Stock Transfer

237 West 37th St. Suite 602
New York, NY 10018

Tel: 212.575.5757

info@equitystock.com

Recent
Filings

View

Corporate Governance

Code of
Ethics

View

Compensation
Committee

View

Audit Committee
Charter

View

Stay up to date with Monogram!

Subscribe to our newsletter for the latest news and innovations.
Don't miss out on valuable insights and updates from the world of orthopedics. Join our community today!

A World Class Team

Our team of extraordinary individuals is on a mission to revolutionize the world of orthopedic medicine, led by experts in running and scaling major tech and medical companies.
Douglas Unis, MD
FOUNDER & CHIEF MEDICAL OFFICER
Benjamin Sexson
CFA, CHIEF EXECUTIVE OFFICER
Kamran Shamaei, PhD
CHIEF TECHNOLOGY OFFICER
Noel Knape
CPA, CHIEF FINANCIAL OFFICER
Muhammad Afnan
DIRECTOR OF SOFTWARE ENGINEERING
Robert Jamieson, DO
BOARD CERTIFIED ORTHOPAEDIC SURGEON AT THE ORTHOPEDIC SPECIALTY CENTER OF NORTHERN CALIFORNIA
Edward M Adler, MD
CHAIR OF THE DEPARTMENT OF ORTHOPEDIC SURGERY AT MOUNT SINAI DOWNTOWN
Gregory Catlett, MD
TOTAL JOINT REPLACEMENT SPECIALIST AT ORTHOPAEDIC SPECIALISTS OF AUSTIN

Key Contact

Chris Tyson

Executive Vice President - MZ North America

Direct: 949-491-8235

MGRM@mzgroup.us

Send us a Message

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

See More from Monogram

Meet the Team

Douglas Unis, MD

Founder & Chief Medical Officer

Dr. Unis is a board-certified attending orthopedic surgeon for the Mount Sinai Health System and Chief of Quality Improvement for Mount Sinai West.

Benjamin Sexson - CEO

CFA, Chief Executive Officer

Prior to joining Monogram, Mr. Sexson served as the Director of R&D and Business Development at Pro-dex (ticker: PDEX). Mr. Sexson graduated with honors from Caltech in Mechanical Engineering and is a CFA Charterholder.

Noel Knape

CFO, Chief Financial Officer

Mr. Knape has over 25 years of experience leading financial departments in multinational, publicly-traded companies. He holds a Master of International Management from the American Graduate School of International Management.

Kamran Shamaei, PhD

CTO

Kamran Shamaei received a Ph.D. from Yale University and MSc from ETH Zurich and did his postdoctoral research at Stanford University, focusing on Medical Robotics. He has extensive experience developing FDA cleared surgical robots.

Kevin Posey

DIRECTOR OF QUALITY AND REGULATORY ASSURANCE

Chris was the Director of Engineering for Orchid Design, a division of Orchid Orthopedic Solutions, a market-leading outsourced medical services. Chris has held various engineering management roles at Medtronic and Smith & Nephew and obtained a Ph.D. in Biomedical Engineering from the University of Iowa.

Muhammad Afnan

DIRECTOR OF SOFTWARE ENGINEERING

Chris was the Director of Engineering for Orchid Design, a division of Orchid Orthopedic Solutions, a market-leading outsourced medical services. Chris has held various engineering management roles at Medtronic and Smith & Nephew and obtained a Ph.D. in Biomedical Engineering from the University of Iowa.

Dr. Roshan Shah

Director of Complex Adult Hip and Knee Reconstruction at Columbia University

Robert Jamieson

Board Certified Orthopaedic Surgeon at The Orthopedic Specialty Center of Northern California

Edward M Adler, MD

CHAIR OF THE DEPARTMENT OF ORTHOPEDIC SURGERY AT MOUNT SINAI DOWNTOWN

Dr. Gregory Catlett

Total Joint Replacement Specialist at Orthopaedic Specialists of Austin

FAQs

Public Offering and Listing

When will Monogram list its shares?
We are in the process of conducting a Regulation A+ offering of our Class A Common Stock and have applied for the listing of our shares on Nasdaq. The offering and listing are expected to occur by the end of May.
I am an existing investor. How can I express my interest in buying shares in the public offering?
Monogram has kicked off the process of moving forward with a public listing to trade on NASDAQ Investors can submit their allocation requests and we can begin the formal allocation of shares by accepting requests with our broker dealer by visiting monogramorthopedics.com.
What will the stock ticker symbol be for Monogram?
We have reserved the ticker symbol, “MGRM.”
What are the tax implications of an equity crowdfunding investment?
We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
What is the offering price per share for Monogram?
The price per share is $7.25 and the minimum purchase is 150 shares or $1087.50.
What is the current valuation for Monogram?
The pre money valuation for the offering is $246M.
Where will Monogram’s shares be traded?
We are applying to list our shares for trading on Nasdaq. Once approved the shares will trade on day following the closing of the offering.
Which class of stock will be listed on Nasdaq?
Monogram intends to list its Class A Common Stock.
When will existing shareholders be able to start trading shares purchased during prior Offerings?
We intend to market the offering for about 60 days. Please note that the shares issued in this offering would not be subject to a lockup. Additionally, on the first day of trading, we anticipate that you will be able to buy more shares in the open market on most trading platforms such as Robinhood, Fidelity, E-Trade or whatever your favorite broker might be. Once the bankers and the Company have determined that we may proceed with the offering, the Company will complete the public listing process and formally notify NASDAQ. The closing will then occur, and trading will begin the next business day.

Please note that SEC Rule 144 mandates that shares purchased under Reg CF (Regulation Crowdfunding) are not eligible for immediate trading and have a 12-month required lock-up period starting from when the investment closed. Equity Stock Transfer has records of when any Reg-CF series-C investments closed. 
Does Monogram pay dividends?
Not at this time.

Transfer Agent

What is a transfer agent?
Transfer agents maintain a record of ownership, including contact information, of an issuer’s registered stockholders. After the Class A Common Stock is listed on NASDAQ, you will be able to deposit any shares into which your Preferred Stock converts with a broker. Until you deposit your shares in a brokerage account, the transfer agent will maintain the record of your ownership. Once you deposit your shares with a broker, the broker will maintain that record.
Who is Monogram’s transfer agent? / How do I trade my stock if I don’t own Common Stock?
Monogram’s transfer agent is Equity Stock Transfer. Stockholders who purchased Preferred Stock will be able to convert their Preferred Stock into Common Stock through Equity Stock Transfer. If you’re a holder of Preferred Stock, please follow the step-by-step instructions to transfer your free trading shares to the broker of your choice - once the Company is listed on Nasdaq:
  • If you have already paid and registered for Online Access to our shareholder portal, and created your username and password, please skip to step 4.
  • To transfer your free trading shares to your broker, you must obtain Online Access here: https://monogram-orthopaedics.equitystock.com/pay and follow the directions. Your DRS (Direct Registration System) transfer agent fees to transfer your shares to your broker are covered when you obtain Online Access.
  • After you complete the payment for Online Access, you will receive email instructions on how to register.
  • Once you have registered and created your username and password, through the Online Access portal, you will be able to download your Common Stock book-entry statement along with a Welcome Letter on how to initiate the DRS process through your broker.
  • Once your broker initiates the DRS process, we will be able to transfer the shares to your brokerage account.

How do I transfer my shares to my brokerage account?
You will need to contact your broker and request to have your shares transferred. Once you have registered and created your username and password, through the Online Access portal, you will be able to download your Common Stock book-entry statement along with a Welcome Letter on how to initiate the process through your broker.
What happens to my stock if the Company cannot contact me?
State law governs the Company’s obligations to surrender stock to the state if it cannot locate a shareholder after a period of time. Thus, shareholders are encouraged to keep their addresses up to date with the transfer agent.
Does Monogram issue 1099’s or K-1’s?
Monogram is a C-Corp and, therefore, does not issue K-1’s.

Prior Investments

I invested through SeedInvest. How do I go about getting my shares to be able to trade them?
The Series A Preferred Stock purchased through SeedInvest are held in street name by New Direction IRA, Inc. Therefore, if you purchased stock through SeedInvest, you will need to work through SeedInvest to convert your stock to Class A Common Stock in order to trade the shares after the Company is listed on Nasdaq. The contact email for SeedInvest is: contactus@seedinvest.com. 
I invested through StartEngine. How do I go about getting my shares to be able to trade them?
Shares purchased through StartEngine are held by our transfer agent. You will be able to manage your shares directly through the transfer agent, Equity Stock Transfer.
I invested through the Reg CF Offering. How do I go about getting my shares to be able to trade them?
Please note that SEC Rule 144 mandates that shares purchased under Reg CF (Regulation Crowdfunding) are not eligible for immediate trading and have a 12-month required lock-up period starting from when the investment closed. Equity Stock Transfer has records of when any Reg-CF series-C investments closed. 

General

Where is Monogram's corporate headquarters?
We are based in the heart of Austin Texas.The corporate address is 3913 Todd Lane, Austin, TX 78744
Where is the company incorporated?
We are a Delaware corporation.
Where can I find the Company’s SEC filings?
All of Monogram’s regulatory filings, include financial reports, can be found here: EDGAR Entity Landing Page (sec.gov)
Who is on the Monogram’s Advisory Board?
Who is on the Monogram’s Management Team?

For Further Information

Who can I contact about specific investor relations questions?
Email: invest@monogramorthopedics.com
Tel: (512)790-5151
Form 1 A
Please visit: https://www.sec.gov/Archives/edgar/data/1769759/000110465923024829/tm237645d1_partiiandiii.html